CUG-252 is under clinical development by Cugene and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase I drugs for Atopic Dermatitis (Atopic Eczema) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CUG-252’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CUG-252 is under development for the treatment of atopic dermatitis, inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus and other autoimmune disorders. The therapeutic candidate is a regulatory T cell (Treg) selective long-acting interleukin 2 (IL 2) fusion protein. It is administered through subcutaneous route.
Cugene is a Pharmaceuticals and Healthcare company that provides medicines for human immune system. The company is Headquartered in Waltham, Massachusetts, The U.S.
For a complete picture of CUG-252’s drug-specific PTSR and LoA scores, buy the report here.